Vitamin D3 for Life

Live Enlightened

Physiology

Intracrine Vitamin D Activity and Cell-Specific Physiology: Full Study

Previous related pageHow Magnesium Supports Vitamin D ActivityNext related pageLocal Activation of Vitamin D in Non-Classical Target Tissues: Full Study
Study at a glance

What question did the studies ask?

Can active vitamin D made by a cell change how that cell or its tissue works? Four core studies examined human immune and skin cells. Two additional mouse reports address tissue development and immune function, but their evidence was reviewed less completely.

What did they find?

In the cell studies, responses depended on the cell’s state, its surroundings and access to the starting vitamin D compound. The developmental mouse study reported temporary changes in growing bone and nearby cells. The newer mouse paper reports changes involving immune function.

What does this mean?

Local vitamin D activation can contribute to particular biological responses. These responses are not all the same, and stronger activity does not automatically mean better health. A signal made by one cell can also affect neighbouring cells.

What are the limits?

The studies do not prove that active vitamin D always stays inside the cell that makes it. Important supporting files from the developmental study were unavailable. The newer immune report is described from its published abstract; its detailed evidence has not been fully assessed here. These findings do not establish a supplement dose or a benefit for patients.

Read the full article below ↓

What changes when a cell can make active vitamin D for local use? The question concerns more than enzyme expression: it asks whether activation changes cellular behaviour or tissue function, and whether the effect can be attributed to action inside the producing cell. This synthesis compares four assessed core studies with two additional, explicitly limited in-vivo reports. It separates evidence of a functional response from evidence of its precise signalling route. For a shorter account of the same evidence, see Intracrine Vitamin D Activity and Cell-Specific Physiology: Study Summary.

EvidencePhysiological contributionImportant limit
Activated human T cells: Kongsbak and ChaussAccess to precursor and activation state affect conversion-linked cell responses.A response in a cell population does not trace every hormone molecule inside one cell.
Human skin systems and mouse wounds: SchauberConversion/receptor-related activity is connected with selected recognition and antimicrobial gene responses.Human CAMP and mouse Camp do not show the same dependence; healing benefit was not measured.
Human macrophage/T-cell comparisons: Villalba LopezProducer state changes local hormone availability and neighbouring-cell responses.The neighbouring-cell route is an alternative to a strictly intracrine interpretation.
Developing mouse cartilage: NajaMain-paper observations connect intended lineage perturbation with developmental tissue differences.Final validation supplements were unavailable; targeting, systemic and version uncertainties remain.
Newer mouse immune report: FroelichAuthors report a T-cell-associated activation-enzyme contribution to immune-effector and host responses.High-level report only here; detailed causal validation is unfinished.
The four core publications and the two additional reports have different evidential roles. The animal reports are not counted as fully qualifying additions to the four-study core.

From conversion to a physiological claim

CYP27B1 is an enzyme that can convert 25-hydroxyvitamin D, a circulating precursor, into calcitriol, the active hormone. Calcitriol can bind the vitamin D receptor, or VDR, and influence cell responses. The conversion and utilisation pathway is already developed in Intracrine conversion and local control of vitamin D metabolism: Full Evidence Review. Here the question is what follows from that capacity in particular biological settings.

Four levels of evidence need to be distinguished. Detecting the enzyme suggests capacity. Showing product formation and a response supports activity within the experimental system. Changing the pathway and observing a changed response strengthens a functional connection. Establishing that the hormone acted inside the same cell before release requires evidence about its route as well. None of these steps automatically establishes a health benefit in people.

Intracrine signalling describes action within the cell where a signal is generated. Autocrine action can involve release followed by action on the producing cell, while paracrine action reaches a neighbouring cell. A tissue can contain more than one route. The anatomical overview in Where Vitamin D Acts identifies different locations of vitamin D action; identifying a location does not, by itself, identify the route used there.

The four core papers were assessed through their principal reports and relevant figures, with remaining source-specific limits retained below. Naja’s final main paper and Figures 1 to 6 were assessed, but its final supplementary files were unavailable. Froelich’s newer immune study is included only as an attributed high-level publication report, with detailed validation unfinished. This is a selected mechanistic synthesis, not a systematic estimate of clinical benefit.

Why the same precursor can produce different cell responses

Kongsbak and colleagues studied activated human T cells and found that timing and the surrounding carrier protein changed their response to the precursor. CYP27B1 and VDR increased around the second and third days of activation, and calcitriol measured in the culture fluid peaked near day three. This matters because an early observation of little production need not describe the same cells later in their activation programme.

Precursor exposure increased the measured CD38 response in serum-free conditions. Inhibiting conversion blocked that precursor-associated response without similarly blocking the response to supplied active hormone. This comparison connects the conversion step with a cellular output more strongly than finding CYP27B1 RNA alone. It remains a cultured-cell experiment, with small, panel-specific numbers of biological experiments rather than a clinical population.

Adding vitamin D-binding protein markedly constrained precursor conversion and responses, whereas responses to supplied active hormone were less affected. The cells could take up carrier protein, but carrier uptake did not guarantee delivery of usable precursor. Total precursor added to a culture therefore did not define its effective availability. The broader activation and removal pathways are introduced in Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).

Villalba Lopez and colleagues made the comparison more physiological in one respect by bringing macrophages and T cells together. Macrophages in the study’s inflammatory activation condition produced more calcitriol, and more rapidly, than the alternative macrophage condition or isolated T cells. With carrier protein present, some macrophage/T-cell cultures retained appreciable production and vitamin D-related response changes when isolated cells were more constrained.

That result is conditional, not evidence of unlimited carrier resistance. Some responses weakened as carrier increased, and the highest tested binding-protein concentration was below the normal-serum concentration cited in the paper. The laboratory macrophage categories are defined activation conditions, not two universal cell types. Small donor groups, variable responses and allogeneic co-culture further limit transfer to intact human tissues.

Read together, these studies show why cellular state and surroundings belong in the physiological explanation. A T-cell response may reflect its own activation machinery, another cell’s production, or both. The neighbouring-cell question is developed separately in Paracrine Vitamin D Signalling: Full Study. It would be misleading to count the macrophage result as another direct demonstration that a hormone remained inside its producer.

Which responses are functionally connected with local activation?

Chauss and colleagues examined a defined human T-cell signalling programme. Activation associated with the complement receptor CD46 increased CYP27B1 and VDR. Reducing CYP27B1, VDR or a component of the linked complement pathway reduced precursor-associated interleukin-10 responses. These perturbations provide evidence that activation and receptor signalling contribute to the measured cellular programme, rather than merely appearing alongside it.

The cytokine pattern is important. In experiments supplying active calcitriol, the hormone reduced interferon-gamma and interleukin-17 programmes while promoting interleukin-6 and interleukin-10. Cytokines are signalling proteins; their names do not give them one fixed beneficial or harmful role. Interleukin-6 has inflammatory roles in other settings, but here it participated in a feedback circuit associated with interleukin-10 production. These downstream responses to supplied active hormone are distinct from the precursor-conversion tests described above; they do not all demonstrate that the responding cells made the hormone themselves.

Blocking the interleukin-6 receptor reduced interleukin-10 and phosphorylated STAT3, a signalling-related form of the STAT3 protein, without producing the same reduction in total STAT3 induction. This separates different parts of the response. Selected genetic observations added mechanistic information, but rare patient-derived cells and small experimental series were not a treatment trial. The work does not establish recovery from viral illness or a universal conversion into regulatory T cells.

Schauber and colleagues addressed a different physiological setting: epidermal responses around injury. Human wound observations, skin-cell systems and receptor/conversion-related interventions connected the vitamin D pathway with CAMP, CD14 and TLR2 responses. CAMP encodes the antimicrobial peptide precursor cathelicidin; CD14 and TLR2 participate in recognising environmental signals. A response-element experiment further connected receptor-responsive DNA regulation with the measured gene response.

The experimental layers have different strengths. Human wound sampling was small, with five wounded and four intact samples in the reported comparison. Inhibitor experiments help test a pathway but are not perfectly specific. Gene or peptide-related measurements do not themselves measure wound closure or infection prevention. No direct concentration of calcitriol inside a single responding keratinocyte was established.

The mouse result also limits a simple generalisation. Wounded mice lacking Cyp27b1 lost the CD14 induction seen in the comparator group, but mouse Camp still increased in both groups and its between-group difference was not statistically significant. This does not replicate a uniformly vitamin D-dependent human CAMP response. The mouse loss was global, so it did not isolate skin-cell activation from every systemic effect.

Thus, a conversion-linked immune feedback programme and an injury-associated epithelial response can both be physiologically meaningful without being the same function. The comparison also explains why “vitamin D boosts immunity” is too vague. The broader metabolic setting is introduced in Tissue-Specific Vitamin D Metabolism, but particular outputs still require their own measurements.

Does a functional response establish a strictly intracellular route?

The strongest common cellular inference is that local activation and receptor-related signalling can contribute to defined responses under particular conditions. That is more informative than enzyme detection. It is still different from demonstrating that newly produced calcitriol acts before leaving its producing cell.

Kongsbak measured product in culture fluid as well as cellular responses. Chauss described an autocrine programme and discussed local feedback. Villalba Lopez showed why a nearby producer changes another cell’s response. These findings make release, return and neighbour effects relevant alternatives; they cannot all be relabelled as exclusive intracellular retention.

This limitation does not make the functional results disappear. It changes the precision of the conclusion: a cell-intrinsic production pathway can matter without every downstream action being strictly intracrine. Likewise, changing a receptor response does not quantify how much hormone was made locally. The distinction between production, removal and downstream gene activity is examined in Tissue-Specific Vitamin D Metabolism and Gene Responses: Full Study.

What does developing cartilage add beyond cell culture?

Naja and colleagues examined developing mice in groups intended to alter Cyp27b1 within the cartilage lineage. The physiological question was whether local activation was associated with growth-plate development and the surrounding process of bone formation and remodelling. The findings extend beyond isolated-cell gene expression, but the missing final validation supplements limit how confidently the intended targeting can be attributed to the specified cells.

In the intended loss group, the hypertrophic region of embryonic cartilage was wider at embryonic day 15.5, but that difference was not present at postnatal day two. At day two, the main-paper bone measurements showed greater trabecular volume, thickness and number, with less separation. That comparison used seven animals per genotype. Later normalisation was reported without displayed data.

More trabecular material at this developmental stage does not automatically mean stronger or healthier bone. It was accompanied by fewer osteoclast-associated cells and is compatible with delayed removal or remodelling of the developing scaffold. The paper also reported reduced vascular-marker expression and fewer vascular-marker-positive cells. Those measurements describe tissue organisation; they do not directly measure blood flow or oxygen delivery.

In the separate overexpression groups, the hypertrophic region was narrower at embryonic day 14.5. Under an additional precursor-exposure condition, neonatal trabecular volume, thickness and number were lower. These are positive opposite-direction findings, but they were not a matched rescue of the loss model: the embryonic comparisons used different ages, and several neonatal bone differences depended on the additional precursor. Under ordinary substrate conditions, several bone and vascular outcomes were reported unchanged. The findings therefore do not form a complete mirror image across every age, marker and condition.

This is a useful in-vivo physiological example because its measured outcomes include developmental architecture and neighbouring cell populations. It is not evidence about adult joint repair, fracture prevention or a supplement programme. Those distinctions are important when reading the wider bone evidence in Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study.

What limits the developmental causal interpretation?

The principal paper reported only about a 47% transcript reduction in a mixed rib preparation. Incomplete targeting and contributions from other cells were possible explanations. The uninspected final supplements include material validation of the intended loss and overexpression models. Consequently, this synthesis can describe the assessed main-paper observations but cannot certify an exclusive or fully validated target-cell intervention.

Several control groups were pooled after the authors reported similar expression or phenotypes; some supporting checks were not displayed or were in unavailable supplementary material. The inspected paper did not establish a comprehensive lineage map or adequately document all safeguards such as blinded histology and litter-adjusted analysis. Small groups, multiple outcomes and possible litter dependence limit the precision of the comparison.

Neonatal calcium did not differ significantly in the displayed comparison of thirteen animals per group. That is a lack of a detected difference at one time, not a formal equivalence test or evidence that all endocrine conditions were identical. Circulating FGF23 was lower at a later measured age, and neonatal FGF23 and circulating calcitriol were not comprehensively established. A purely local explanation cannot be assumed from the calcium result.

Version differences also matter. Roy Pascal Naja’s October 2008 McGill PhD thesis, The role of Vitamin D metabolic enzymes in bone development and repair (archive NR66619; OCLC 778188046), reported no RANKL difference in relevant comparisons. Only selected indexed thesis text passages were examined; its complete text and figure images were not inspected. The final publication reported lower RANKL in the intended loss group and higher RANKL in the overexpression comparison. RANKL helps regulate osteoclast development. The versions are not independent studies or interchangeable sources for the missing final supplements. Their difference does not establish misconduct, but the available record does not resolve the pathway discrepancy.

Finally, osteoclast and vascular observations concern cells neighbouring the intended cartilage population. They could involve local hormone movement or other signals produced downstream. The study did not directly trace calcitriol production and retention in a single chondrocyte. Its developmental observations support physiological relevance while leaving the exact intracellular route and complete causal chain unresolved.

What does the newer in-vivo immune report add?

Froelich and colleagues’ 2026 publication reports a T-cell Cyp27b1 comparison linked to granzyme B expression and antiviral host responses in a mouse influenza model. Granzyme B is an immune-effector protein. The report is directly relevant to whether a cell-associated activation pathway contributes to function in a living animal, and it addresses a different physiological question from cartilage development.

Its potential importance should not be obscured by the older paper’s more accessible main figures. An in-vivo immune-function comparison can bear more directly on that question than a culture response alone. It also prevents treating local vitamin D activity as necessarily equivalent to suppressing inflammatory responses: an effector or host-response function needs its own assessment.

Here, however, the publication is represented only at the verified, non-operational abstract-report level. Detailed validation-dependent assessment remains unfinished. No effect size, complete rescue, exclusive lineage attribution or intracellular retention is established by this account. The paper is not counted as a fully assessed fifth core study, and its mouse findings are not evidence of human infection prevention or treatment.

How the cellular and animal evidence fit together

The studies contribute different parts of the physiological argument. The human-cell core tests availability, conversion-linked responses, receptor-associated regulation and a neighbouring producer’s influence. The developmental mouse paper adds observed tissue consequences, but with incomplete targeting validation and systemic and version qualifications. The newer immune report identifies a directly relevant living-animal functional result whose detailed appraisal is still unfinished.

This combination supports a graded conclusion. Particular cells can generate and respond to local vitamin D signals, and changing the pathway can change measured biological responses. Evidence of tissue consequences exists and should be examined, not dismissed because its attribution remains uncertain. At the same time, an observed consequence does not prove every proposed intermediate step or the hormone’s intracellular itinerary.

The direction of a response must also stay specific. Increased interleukin-10, altered antimicrobial-gene expression, a temporary change in trabecular structure and an immune-effector report are not interchangeable measures of improvement. Their significance depends on the model, timing, comparator and outcome. A physiological effect can be real without being uniformly beneficial.

The four core publications are distinct studies, not four independent laboratories proving one universal mechanism. Kongsbak and Villalba Lopez share a Copenhagen research programme; donor overlap was not established. Several assay arms within a paper remain one underlying study. Naja’s thesis and final publication likewise cannot be counted as two confirmations. These relationships affect the strength of replication without erasing the studies’ different contributions.

What can be concluded for physiology and for readers?

The evidence supports conditional physiological roles for local vitamin D activation in selected cells and experimental tissues. It is strongest where changing a pathway is connected with a measured response and the model’s limitations remain visible. Cell state, precursor availability, receptor signalling and communication with neighbouring cells help explain why the same biochemical reaction can contribute to different outcomes.

Strict intracellular retention, fully resolved lineage attribution in the selected animal examples, and a general benefit in patients remain different and incompletely established propositions. A blood measurement cannot directly specify every local process, but these studies do not provide a validated alternative test for an individual or explain every difference in symptoms between people.

Nor do a cell response or a developmental phenotype establish improved recovery or adaptation to a challenge. The separate clinical and experimental question is examined in Vitamin D and Adaptive Capacity: Full Study. This synthesis does not establish a personal supplement dose, a safety guarantee from local feedback, or a treatment strategy. Its value is a clearer account of what local activation can contribute and where the evidence stops.

Sources

Related reading

Original sources

Source

Vitamin D-binding protein controls T cell responses to vitamin D

In vitro studies have shown that the active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation.

Publication details

Vitamin D-binding protein controls T cell responses to vitamin D. Kongsbak M, von Essen MR, Levring TB, et al. BMC immunology. 2014;15:35. DOI: 10.1186/s12865-014-0035-2.

Read more →
Source

Chondrocyte-Specific Modulation of Cyp27b1 Expression Supports a Role for Local Synthesis of 1,25-Dihydroxyvitamin D3 in Growth Plate Development

Published in Naja RP, Dardenne O, Arabian A, et al. Endocrinology (2009).

Publication details

Chondrocyte-Specific Modulation of Cyp27b1 Expression Supports a Role for Local Synthesis of 1,25-Dihydroxyvitamin D3 in Growth Plate Development. Naja RP, Dardenne O, Arabian A, et al. Endocrinology. 2009;150(9):4024 to 4032. DOI: 10.1210/en.2008-1410.

Read more →